Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID JAY COHEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1487652020
CMS profile
158374
Location
MACON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$540,258.48

558 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID JAY COHEN

NPI 1487652020 · CMS profile ID 158374

Allopathic & Osteopathic Physicians / Dermatology

MACON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

558 matching records · $540,258.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 558 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 551–558 of 558.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $40.8801/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224422532 CMS
UCB, Inc. $58.7401/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224422534 CMS
UCB, Inc. $65.0001/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224422536 CMS
UCB, Inc. $85.0001/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224422538 CMS
UCB, Inc. $127.2301/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224422540 CMS
UCB, Inc. $333.1601/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224422542 CMS
UCB, Inc. $636.9501/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224422544 CMS
Regeneron Healthcare Solutions, Inc. $8,967.0001/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212892919 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $492,370.66 607
PY2020 $158,352.86 216
PY2021 $382,319.72 445
PY2022 $407,009.50 517
PY2023 $438,339.95 571
PY2024 $449,437.85 594
PY2025 $540,258.48 558

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $350,254.20 48
PY2024 Principal investigator $274,007.04 102
PY2023 Principal investigator $255,431.31 95
PY2022 Recipient $480.08 2
PY2022 Principal investigator $124,993.10 42
PY2021 Recipient $1,652.03 3
PY2021 Principal investigator $481,218.52 59
PY2020 Recipient $3,012.86 7
PY2020 Principal investigator $518,166.62 80
PY2019 Recipient $13,664.30 6
PY2019 Principal investigator $648,880.49 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $3,519.00 12/22/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226127468
Principal investigator 1 SANOFI US SERVICES INC. $21,489.00 12/08/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $695.81 12/04/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184269237
Principal investigator 1 Janssen Research & Development, LLC $1,665.00 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390521
Principal investigator 1 SANOFI US SERVICES INC. $7,920.00 11/17/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226127461
Principal investigator 1 SANOFI US SERVICES INC. $11,478.00 10/27/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.72 10/23/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252626
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,016.83 10/03/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,907.39 10/03/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244669
Principal investigator 1 Janssen Research & Development, LLC $1,390.00 10/02/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175208748
Principal investigator 1 Janssen Research & Development, LLC $1,509.00 09/04/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390501
Principal investigator 1 Janssen Research & Development, LLC $1,875.00 09/04/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390514
Principal investigator 1 SANOFI US SERVICES INC. $27,759.00 09/03/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $722.47 08/14/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184228319
Principal investigator 1 SANOFI US SERVICES INC. $10,423.00 08/11/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127453
Principal investigator 1 SANOFI US SERVICES INC. $3,826.00 08/04/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $807.90 07/17/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217076
Principal investigator 1 SANOFI US SERVICES INC. $9,758.00 07/14/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127434
Principal investigator 1 SANOFI US SERVICES INC. $7,853.60 07/14/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $438.91 06/12/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184206261
Principal investigator 1 SANOFI US SERVICES INC. $9,556.00 06/09/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127427
Principal investigator 1 SANOFI US SERVICES INC. $25,423.50 05/19/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,045.63 05/15/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184194637
Principal investigator 1 Janssen Research & Development, LLC $3,105.00 04/28/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175209022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184189185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $232.50 04/23/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184189187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184189191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,614.60 04/15/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184183412
Principal investigator 1 Novartis Pharmaceuticals Corporation $874.06 04/09/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307247
Principal investigator 1 SANOFI US SERVICES INC. $10,800.00 04/02/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226127417
Principal investigator 1 SANOFI US SERVICES INC. $12,399.00 04/02/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127425
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,849.52 03/31/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307245
Principal investigator 1 Janssen Research & Development, LLC $2,132.00 03/27/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,207.21 03/11/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184170866
Principal investigator 1 SANOFI US SERVICES INC. $32,185.50 03/10/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127423
Principal investigator 1 Janssen Research & Development, LLC $2,074.00 03/06/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175208555
Principal investigator 1 Janssen Research & Development, LLC $1,131.00 03/06/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175208692
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 03/06/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175209220
Principal investigator 1 Janssen Research & Development, LLC $3,212.00 03/03/2025 Non-covered Recipient Entity
Dermatologic Surg Specialists PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175208942
Principal investigator 1 Eli Lilly and Company $9,375.60 02/25/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGICAL SPECIALISTS
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187882472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,541.77 02/25/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155412
Principal investigator 1 SANOFI US SERVICES INC. $14,743.60 02/24/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226127414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155078
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 02/18/2025 Non-covered Recipient Entity
Skin Care Physicians Of Georgia
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226127410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,961.25 01/17/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148123
Principal investigator 1 Eli Lilly and Company $10,751.15 01/07/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGICAL SPECIALISTS
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187878189
Principal investigator 1 Eli Lilly and Company $5,517.35 01/07/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGICAL SPECIALISTS
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187878727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.58 01/07/2025 Non-covered Recipient Entity
DERMATOLOGIC SURGERY SPECIALISTS PC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184145856